β-Hydroxybutyrate Ameliorates Aβ-Induced Downregulation of TrkA Expression by Inhibiting HDAC1/3 in SH-SY5Y Cells

Am J Alzheimers Dis Other Demen. 2020 Jan-Dec:35:1533317519883496. doi: 10.1177/1533317519883496. Epub 2019 Oct 24.

Abstract

Tyrosine kinase receptor A (TrkA) plays an important role in the protection of cholinergic neurons in Alzheimer's disease (AD). This study was designed to investigate whether β-hydroxybutyrate (BHB), an endogenous histone deacetylase (HDAC) inhibitor, upregulates the expression of TrkA by affecting histone acetylation in SH-SY5Y cells treated with amyloid β-protein (Aβ). The results showed that BHB ameliorated the reduction of cell vitality and downregulation of TrkA expression induced by Aβ. Furthermore, BHB inhibited the upregulation of HDAC1/2/3 expression and downregulation of histone acetylation (Ace-H3K9 and Ace-H4K12) levels in Aβ-treated cells. The expression of TrkA was upregulated in HDAC1- or 3-silenced SH-SY5Y cells. However, there was no significant difference in TrkA expression between the HDAC2 knockdown and control cells. In conclusion, this study demonstrates that BHB protects against Aβ-induced neurotoxicity in SH-SY5Y cells. The underlying mechanism of the effect may be associated with the upregulation of TrkA expression by inhibiting HDAC1/3.

Keywords: Alzheimer’s disease; histonedeacetylases; tyrosine kinase receptor A; β-hydroxybutyrate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Hydroxybutyric Acid / pharmacology*
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / metabolism*
  • Cell Culture Techniques
  • Down-Regulation*
  • Histone Deacetylase 1*
  • Humans
  • Receptor Protein-Tyrosine Kinases / metabolism*

Substances

  • Amyloid beta-Peptides
  • Receptor Protein-Tyrosine Kinases
  • HDAC1 protein, human
  • Histone Deacetylase 1
  • 3-Hydroxybutyric Acid